Business Context and Reporting Period
This Form 8-K Current Report was filed by Elicio Therapeutics, Inc. on July 2, 2026, reporting events occurring on July 1, 2026. The Company is a Delaware corporation and an emerging growth company with its principal executive offices in Boston, Massachusetts. Its common stock trades on The Nasdaq Capital Market under the symbol ELTX.
Key Financial Metrics and Transaction Details
The filing details a registered direct offering of common stock. Key transaction metrics include:
- Shares Issued: 4,380,313 shares of Common Stock.
- Offering Price: $3.43 per share.
- Gross Proceeds: Approximately $15 million (before deducting placement agents' fees and offering expenses).
- Placement Agents: Titan Partners Group, LLC (lead) and B. Riley Securities, Inc. (co-placement agent).
- Expected Closing Date: July 6, 2026.
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity, as this report focuses on a capital raise event rather than periodic financial performance.
Material Changes and Agreements
On July 1, 2026, the Company entered into a Securities Purchase Agreement with certain institutional investors. Material terms include:
- Issuance Restrictions: The Company agreed to restrictions on the issuance and sale of Common Stock or Common Stock Equivalents for a 30-day period following the closing of the Offering.
- Registration: The shares were offered pursuant to a registration statement on Form S-3 (File No. 333-293861), declared effective on March 16, 2026.
Outlook, Risks, and Management Commentary
The Company issued a press release on July 1, 2026, announcing the pricing of the Offering. The filing notes that the Offering is expected to close on July 6, 2026, subject to customary closing conditions. No specific forward-looking guidance, risk factors, or management commentary regarding future operations or financial outlook is provided within the text of this specific 8-K filing.
Investor Verification Checklist
- Verify the final closing date of the Offering (expected July 6, 2026) and confirm receipt of net proceeds after fees.
- Review the full Securities Purchase Agreement (Exhibit 10.1) for specific covenants and the definition of "Common Stock Equivalents" subject to the 30-day lock-up.
- Confirm the exact amount of placement agent fees and offering expenses to calculate net proceeds.
- Check subsequent filings for any updates on the use of proceeds or changes to the Company's capital structure.